Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 3/2016

01-05-2016 | Original Article

Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice

Authors: Xing-Li Meng, Taniqua S. Day, Nathan McNeill, Paula Ashcraft, Thomas Frischmuth, Seng H. Cheng, Zhi-Ping Liu, Jin-Song Shen, Raphael Schiffmann

Published in: Journal of Inherited Metabolic Disease | Issue 3/2016

Login to get access

Abstract

Fabry disease is caused by deficient activity of α-galactosidase A and subsequent intracellular accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3). Vascular endothelial cells may play important roles in disease pathogenesis, and are one of the main target cell types in therapeutic interventions. In this study, we generated immortalized aortic endothelial cell lines from a mouse model of Fabry disease. These cells retained endothelial cell-specific markers and functions. Gb3 expression level in one of these clones (referred to as FMEC2) was highly susceptible to culture media, and appeared to be regulated by glucosylceramide synthase. Results also showed that Gb3 could be upregulated by hydrocortisone. FMEC2 express the mannose 6-phosphate receptor and sortilin but not the mannose receptor. Uptake studies suggested that sortilin plays a role in the binding and internalization of mammalian cell-produced α-galactosidase A. Moss-aGal (a plant-made enzyme) was endocytosed by FMEC2 via a receptor other than the aforementioned receptors. In conclusion, this study suggests that glucosylceramide synthase and hydrocortisone may play important roles in modulating Gb3 levels in Fabry mouse aortic endothelial cells, and that endocytosis of recombinant α-galactosidase A involves a combination of multiple receptors depending on the properties of the enzyme.
Appendix
Available only for authorised users
Literature
go back to reference Bangari DS, Ashe KM, Desnick RJ et al (2015) alpha-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Am J Pathol 185:651–665CrossRefPubMed Bangari DS, Ashe KM, Desnick RJ et al (2015) alpha-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Am J Pathol 185:651–665CrossRefPubMed
go back to reference Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 276:1163–1167CrossRefPubMed Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 276:1163–1167CrossRefPubMed
go back to reference Bu G, Marzolo MP (2000) Role of rap in the biogenesis of lipoprotein receptors. Trends Cardiovasc Med 10:148–155CrossRefPubMed Bu G, Marzolo MP (2000) Role of rap in the biogenesis of lipoprotein receptors. Trends Cardiovasc Med 10:148–155CrossRefPubMed
go back to reference Cabrera-Salazar MA, Deriso M, Bercury SD et al (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One 7:e43310CrossRefPubMedPubMedCentral Cabrera-Salazar MA, Deriso M, Bercury SD et al (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One 7:e43310CrossRefPubMedPubMedCentral
go back to reference Christensen EI, Zhou Q, Sorensen SS et al (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18:698–706CrossRefPubMed Christensen EI, Zhou Q, Sorensen SS et al (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18:698–706CrossRefPubMed
go back to reference Coutinho MF, Prata MJ, Alves S (2012) A shortcut to the lysosome: the mannose-6-phosphate-independent pathway. Mol Genet Metab 107:257–266CrossRefPubMed Coutinho MF, Prata MJ, Alves S (2012) A shortcut to the lysosome: the mannose-6-phosphate-independent pathway. Mol Genet Metab 107:257–266CrossRefPubMed
go back to reference Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774 Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
go back to reference Futerman AH, Pagano RE (1991) Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem J 280(Pt 2):295–302CrossRefPubMedPubMedCentral Futerman AH, Pagano RE (1991) Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem J 280(Pt 2):295–302CrossRefPubMedPubMedCentral
go back to reference Heare T, Alp NJ, Priestman DA et al (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30:79–87CrossRefPubMed Heare T, Alp NJ, Priestman DA et al (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30:79–87CrossRefPubMed
go back to reference Heuser JE, Anderson RG (1989) Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J Cell Biol 108:389–400CrossRefPubMed Heuser JE, Anderson RG (1989) Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J Cell Biol 108:389–400CrossRefPubMed
go back to reference Hu F, Padukkavidana T, Vaegter CB et al (2010) Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68:654–667CrossRefPubMedPubMedCentral Hu F, Padukkavidana T, Vaegter CB et al (2010) Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68:654–667CrossRefPubMedPubMedCentral
go back to reference Kang JJ, Shu L, Park JL, Shayman JA, Bodary PF (2014) Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-galactosidase A. Am J Physiol Gastrointest Liver Physiol 306:G140–G146CrossRefPubMed Kang JJ, Shu L, Park JL, Shayman JA, Bodary PF (2014) Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-galactosidase A. Am J Physiol Gastrointest Liver Physiol 306:G140–G146CrossRefPubMed
go back to reference Larsen JV, Hansen M, Moller B et al (2010) Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. Mol Cell Biol 30:4175–4187CrossRefPubMedPubMedCentral Larsen JV, Hansen M, Moller B et al (2010) Sortilin facilitates signaling of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor receptor beta heterodimer. Mol Cell Biol 30:4175–4187CrossRefPubMedPubMedCentral
go back to reference Marchesan D, Cox TM, Deegan PB (2012) Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. J Inherit Metab Dis 35:1107–1117CrossRefPubMed Marchesan D, Cox TM, Deegan PB (2012) Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. J Inherit Metab Dis 35:1107–1117CrossRefPubMed
go back to reference Marcusson EG, Horazdovsky BF, Cereghino JL, Gharakhanian E, Emr SD (1994) The sorting receptor for yeast vacuolar carboxypeptidase Y is encoded by the VPS10 gene. Cell 77:579–586CrossRefPubMed Marcusson EG, Horazdovsky BF, Cereghino JL, Gharakhanian E, Emr SD (1994) The sorting receptor for yeast vacuolar carboxypeptidase Y is encoded by the VPS10 gene. Cell 77:579–586CrossRefPubMed
go back to reference Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512CrossRefPubMed Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512CrossRefPubMed
go back to reference Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM (1999) Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J Biol Chem 274:8832–8836CrossRefPubMed Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM (1999) Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J Biol Chem 274:8832–8836CrossRefPubMed
go back to reference Nielsen MS, Madsen P, Christensen EI et al (2001) The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J 20:2180–2190CrossRefPubMedPubMedCentral Nielsen MS, Madsen P, Christensen EI et al (2001) The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J 20:2180–2190CrossRefPubMedPubMedCentral
go back to reference Nishie T, Hikimochi Y, Zama K et al (2010) Beta4-galactosyltransferase-5 is a lactosylceramide synthase essential for mouse extra-embryonic development. Glycobiology 20:1311–1322CrossRefPubMed Nishie T, Hikimochi Y, Zama K et al (2010) Beta4-galactosyltransferase-5 is a lactosylceramide synthase essential for mouse extra-embryonic development. Glycobiology 20:1311–1322CrossRefPubMed
go back to reference Nykjaer A, Lee R, Teng KK et al (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843–848CrossRefPubMed Nykjaer A, Lee R, Teng KK et al (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427:843–848CrossRefPubMed
go back to reference Park JL, Whitesall SE, D’Alecy LG, Shu L, Shayman JA (2008) Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35:1156–1163CrossRefPubMedPubMedCentral Park JL, Whitesall SE, D’Alecy LG, Shu L, Shayman JA (2008) Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35:1156–1163CrossRefPubMedPubMedCentral
go back to reference Petersen CM, Nielsen MS, Nykjaer A et al (1997) Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 272:3599–3605CrossRefPubMed Petersen CM, Nielsen MS, Nykjaer A et al (1997) Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 272:3599–3605CrossRefPubMed
go back to reference Prabakaran T, Nielsen R, Larsen JV et al (2011) Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. PLoS One 6:e25065CrossRefPubMedPubMedCentral Prabakaran T, Nielsen R, Larsen JV et al (2011) Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. PLoS One 6:e25065CrossRefPubMedPubMedCentral
go back to reference Prabakaran T, Nielsen R, Satchell SC et al (2012) Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells. PLoS One 7:e39975CrossRefPubMedPubMedCentral Prabakaran T, Nielsen R, Satchell SC et al (2012) Mannose 6-phosphate receptor and sortilin mediated endocytosis of alpha-galactosidase A in kidney endothelial cells. PLoS One 7:e39975CrossRefPubMedPubMedCentral
go back to reference Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR (2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92:137–144CrossRefPubMedPubMedCentral Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR (2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92:137–144CrossRefPubMedPubMedCentral
go back to reference Shen JS, Meng XL, Wight-Carter M et al (2015a) Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 24:3181–3191 Shen JS, Meng XL, Wight-Carter M et al (2015a) Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 24:3181–3191
go back to reference Shen JS, Busch A, Day TS, et al (2015b) Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis doi:10.1007/s10545-015-9886-9 Shen JS, Busch A, Day TS, et al (2015b) Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis doi:10.​1007/​s10545-015-9886-9
go back to reference Shu L, Murphy HS, Cooling L, Shayman JA (2005) An in vitro model of Fabry disease. J Am Soc Nephrol 16:2636–2645CrossRefPubMed Shu L, Murphy HS, Cooling L, Shayman JA (2005) An in vitro model of Fabry disease. J Am Soc Nephrol 16:2636–2645CrossRefPubMed
go back to reference Sillence DJ, Puri V, Marks DL et al (2002) Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res 43:1837–1845CrossRefPubMed Sillence DJ, Puri V, Marks DL et al (2002) Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res 43:1837–1845CrossRefPubMed
go back to reference Sorvillo N, Pos W, van den Berg LM et al (2012) The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 119:3828–3835CrossRefPubMed Sorvillo N, Pos W, van den Berg LM et al (2012) The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 119:3828–3835CrossRefPubMed
go back to reference Takahashi K, Donovan MJ, Rogers RA, Ezekowitz RA (1998) Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res 292:311–323CrossRefPubMed Takahashi K, Donovan MJ, Rogers RA, Ezekowitz RA (1998) Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res 292:311–323CrossRefPubMed
go back to reference Troussard AA, Khallou J, Mann CJ et al (1995) Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein. J Biol Chem 270:17068–17071CrossRefPubMed Troussard AA, Khallou J, Mann CJ et al (1995) Inhibitory effect on the lipolysis-stimulated receptor of the 39-kDa receptor-associated protein. J Biol Chem 270:17068–17071CrossRefPubMed
go back to reference Wagner DD, Olmsted JB, Marder VJ (1982) Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 95:355–360CrossRefPubMed Wagner DD, Olmsted JB, Marder VJ (1982) Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 95:355–360CrossRefPubMed
Metadata
Title
Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice
Authors
Xing-Li Meng
Taniqua S. Day
Nathan McNeill
Paula Ashcraft
Thomas Frischmuth
Seng H. Cheng
Zhi-Ping Liu
Jin-Song Shen
Raphael Schiffmann
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 3/2016
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9920-6

Other articles of this Issue 3/2016

Journal of Inherited Metabolic Disease 3/2016 Go to the issue

Acknowledgement to referees

Acknowledgement to referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.